StimOxyGen
2 known investors
StimOxyGen develops a pH-sensitive polymer-coated nanoparticle formulation that dissolves in low-pH environments and transiently generates oxygen within hypoxic solid tumours to improve the efficacy of cancer treatments such as radiotherapy and chemotherapy. The nanoparticle can also carry additional therapeutic payloads on its polymer coating.
BiotechDeep TechMedical Devices
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- STIMOXYGEN LTD
- Company number
- NI677236
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 9 Mar 2021
- Registered office
- C/O A&L Goodbody Northern Ireland Llp, 42-46 Fountain Street, Belfast, BT1 5EF
- Nature of business (SIC)
- 32500 — Manufacture of medical and dental instruments and supplies72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 8 Mar 2026 · next due 22 Mar 2027
Current officers · 5
- Sarcon Compliance Limited — corporate secretary, appointed 9 Mar 2021
- Fergus Begley — director, appointed 7 Dec 2021
- Sian Farrell — director, appointed 9 Mar 2021
- Anthony Mchale — director, appointed 9 Mar 2021
- Leslie James Russell — director, appointed 9 Mar 2021
Source: Companies House public register · retrieved 9 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does StimOxyGen do?
- StimOxyGen develops a pH-sensitive polymer-coated nanoparticle formulation that dissolves in low-pH environments and transiently generates oxygen within hypoxic solid tumours to improve the efficacy of cancer treatments such as radiotherapy and chemotherapy. The nanoparticle can also carry additional therapeutic payloads on its polymer coating.
- Who are StimOxyGen's investors?
- StimOxyGen's investors include Clarendon Fund Managers Ltd., DSW Ventures.